Eli Lilly & Co. (LLY) Announces Abemaciclib neoMONARCH Phase 2 Met Primary Endpoint
Tweet Send to a Friend
Eli Lilly and Company (NYSE: LLY) announced that the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE